WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition
(1995; 152 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
Open this folder and view contentsProtozoa
Close this folderHelminths
Close this folderCestode (tapeworm) infection
View the documentAlbendazole
View the documentMebendazole
View the documentNiclosamide
View the documentPraziquantel
Open this folder and view contentsIntestinal nematode infection
View the documentTissue nematode infections
Open this folder and view contentsLoiasis
Open this folder and view contentsLymphatic filariasis
Open this folder and view contentsOnchocerciasis
Open this folder and view contentsSchistosomiasis
Open this folder and view contentsIntestinal, liver and lung flukes
View the documentSelected WHO publications of related interest
View the documentBack cover


Group: anthelminthic agent
Chewable tablet 200 mg, 400 mg

General information

A benzimidazole derivative that interferes with micro tubule assembly and blocks glucose uptake by many intestinal and tissue nematodes and some cestodes.

It is poorly absorbed from the gastrointestinal tract and is rapidly and extensively metabolized in the liver. The absorbed fraction, which has a plasma half-life of some 8 hours, is largely eliminated in the bile and urine as the sulfoxide.

Clinical information


Treatment of Echinococcus multilocularis infections, E. granulosus infections prior to or not amenable to surgery, and neurocysticercosis.

Dosage and administration

Cystic echinococcosis

Adults: up to four 30-day courses of 10-15 mg/kg daily in two divided doses separated by treatment-free periods of 15 days. Patients with E. multilocularis infections may need further treatment cycles.


Adults: 15 mg/kg daily for 30 days. Early data suggest that an 8-day course may be as effective.


• Known hypersensitivity.
• Pregnancy.


Liver function and blood counts should be monitored at least twice during each cycle of treatment and further treatment cycles should not be initiated unless values are within normal limits.

Use in pregnancy

Albendazole has been shown to have teratogenic and embryotoxic potential in rats and rabbits. It should not be administered during confirmed or suspected pregnancy.

Adverse reactions

Transient gastrointestinal discomfort and headache have occasionally been reported.

Reversible increases in serum levels of hepatic enzymes and reversible reductions in leukocyte counts occur.

Rash and fever have been reported rarely during the early stages of treatment. Alopecia has been reported in a small percentage of patients.


Emesis or gastric lavage may be of value if undertaken within a few hours of ingestion. Otherwise treatment is symptomatic and supportive. No specific antidote exists.


Tablets should be stored in well-closed containers.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018